Eliciting patients' preferences for outpatient treatment of febrile neutropenia: A discrete choice experiment

Supportive Care in Cancer

Volumn 21, Issue 1, 2013, Pages 245-251

  Lathia, Nina ^a,b   Isogai, Pierre K ^b   Walker, Scott E ^a,b   De Angelis, Carlo ^a,b   Cheung, Matthew C ^b   Hoch, Jeffrey S ^a,c,d   Mittmann, Nicole ^b,e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Pharmacoeconomics Research Unit   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Discrete choice experiment; Febrile neutropenia; Health services research; Preferences

Indexed keywords

ADULT; AGED; ARTICLE; CAREGIVER; CONTROLLED STUDY; COST OF ILLNESS; DISCRETE CHOICE EXPERIMENT QUESTIONNAIRE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL INFORMATION; OUTPATIENT; OUTPATIENT CARE; PATIENT ASSESSMENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAREGIVERS; FEMALE; FEVER; FINANCING, PERSONAL; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; ONTARIO; PATIENT PREFERENCE;

EID: 84874105095     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1517-5     Document Type: Article

References (23)

1. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266
2. Lathia N, Mittmann N, DeAngelis C et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742-748
3. Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215-222
4. Innes H, Lim SL, Hall A et al (2008) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485-491
5. Innes HE, Smith DB, O'Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43-49
6. Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134
7. Mizuno T, Katsumata N, Mukai H et al (2007) The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 15:287-291
8. Rolston KV, Manzullo EF, Elting LS et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106:2489-2494
9. Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12:478-483
10. Elting LS, Lu C, Escalante CP et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606-611
11. Hendricks A, Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29:3984-3989
12. Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. Brit Med J 320:1530-1533
13. King MT, Hall J, Lancsar E et al (2007) Patient preferences for managing asthma: results from a discrete choice experiment. Health Econ 16:703-717
14. Phillips KA, Maddala T, Johnson FR (2002) Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 37:1681-1705
15. Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B (2005) Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 28:2243-2245
16. Bryan S, Gold L, Sheldon R, Buxton M (2009) Preference measurement using conjoint methods: an empirical investigation of reliability. Health Econ 9:385-395
17. Ryan M, Watson V, Amaya-Amaya M (2003) Methodological issues in the monetary valuation of benefits in healthcare. Exp Rev Pharmacoecon Outcomes Res 3:717-727
18. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology Prevention and Treatment of Cancer-Related Infections V.2.2009. Available at http://www.nccn.org/professionals/physician-gls/pdf/ infections.pdf. Accessed 14 April 2011.
19. Street DJ, Burgess L, Louviere JL (2005) Quick and easy choice sets: constructing optimal and nearly optimal stated choice experiments. Int J Res Mark 22:459-470
20. Dranitsaris G, Tran TM (1995) Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 31A:2174-2180
21. Leese B, Collin R, Clark DJ (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. PharmacoEconomics 6:233-239
22. Montero MC, Valdivia ML, Carvajal E et al (1994) Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 16:187-192
23. Stommel M, Given CW, Bam G (1993) The cost of cancer home care to families. Cancer 71:867-1874